All In Biotech

NDA 216227 · Harrow Eye

Iheezo

Chloroprocaine Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Sep 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 27, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

44

7 Phase 3, 4 recruiting

FAERS reports

108

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 24, 2026.

IHEEZO TM is indicated for ocular surface anesthesia. IHEEZO TM is an ester anesthetic indicated for ocular surface anesthesia. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • IHEEZO · CHLOROPROCAINE HYDROCHLORIDE 3% · GEL, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloroprocaine" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective55
  • underdose54
  • eye irritation21
  • eye pain20
  • ocular hyperaemia8
  • lacrimation increased7
  • ocular discomfort7
  • product temperature excursion issue7
  • conjunctival hyperaemia6
  • off label use5
  • vision blurred3
  • corneal abrasion2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20242
202512
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Iheezo (Chloroprocaine HCL/PF) · HCPCS J2403

2024 spending

$47.0M

Beneficiaries

37,681

86,752 claims

Per beneficiary

$1,248

2024 ASP limit $0.64 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$7,767,626
2024$47,036,876

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.